TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06341218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pediatric Cardiopulmonary Resuscitation Training Based On Team Resource Management
Description: The sociodemographic information form, Pediatric CPR knowledge level and teamwork attitudes pretest were administered to the healthcare teams just before the training intervention.~The intervention group received a 3-hour training intervention on technical/non-technical skills for CRM-Based Pediatric CPR Training To measure pediatric CPR team performance, 5 different scenarios were prepared by the researcher by INACLS standards. One day after the training intervention, simulation application including pediatric cardiac arrest scenarios was applied to all CPR teams in the intervention(5 groups) and control(5 groups) groups. The scenario content was based on a 5-year-old male patient diagnosed with Pneumonia+Septic Shock.~Pediatric CPR skill levels of the healthcare teams were evaluated during the simulation practice. Immediately after the simulation, the post-intervention post-test of Pediatric CPR knowledge level and team attitudes of the healthcare teams was performed.
Study: NCT06415201

Intervention type: OTHER
Intervention: Interactive Artificial Intelligence
Description: scenario based AI to assess, classify, explain and conduct supportive interviews
Study: NCT05904964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab vedotin
Description: Disitamab Vedotin 2mg/kg was injected every 2 weeks,

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine therapy
Description: Doctors choose endocrine therapy independently
Study: NCT05226013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyglycol lated urate oxidase for injection
Description: Single dose escalation
Study: NCT05235880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality based games
Description: In an hour physiotherapy session first 40 minutes of session includes conventional physiotherapy program tailored to patient's needs. Last 20 minutes of session includes virtual reality based games aiming improvement on upper extremities, trunk and cognitive functions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercises
Description: In an hour physiotherapy session first 40 minutes of session includes conventional physiotherapy program tailored to patient's needs. Last 20 minutes of session includes conventional physiotherapy approaches aiming improvement on upper extremities, trunk and cognitive functions.
Study: NCT05226013

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05542368

Intervention type: DIAGNOSTIC_TEST
Intervention: Thyroid tests
Description: Thyroid function test TSH ,T3,T4 Thyroid antibody test anti TPO,antithyroglobulin

Intervention type: DIAGNOSTIC_TEST
Intervention: Thyroid tests
Description: Thyroid function test TSH ,T3,T4 Thyroid antibody test anti TPO,antithyroglobulin
Study: NCT06196723

Intervention type: PROCEDURE
Intervention: transjugular intrahepatic portal shunt
Description: TIPS was performed by experienced clinicians in the Gastroenterology/Hepatology Department according to standard operating procedures, utilizing 8 mm or 10 mm expanded polytetrafluoroethylene-covered stents at the discretion of the local physician.
Study: NCT05562713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Present Bias without Loss Aversion
Description: Small prize for each step completed; large prize for independent CIC

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Present Bias with Loss Aversion
Description: Prizes only if fully independent CIC demonstrated
Study: NCT05789615

Intervention type: DRUG
Intervention: Letermovir
Description: Letermovir has achieved excellent therapeutic benefits globally but is still in its infancy in China. Letermovir obtained an implied license for a clinical trial in June 2020, and in November 2020, Letermovir submitted and accepted four new drug marketing applications in China, including injection and tablet formulations. On December 31, 2021, the China National Medical Products Administration (NMPA) approved letermovir for cytomegalovirus (CMV) seropositive adult recipients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) \[R+\] prevention of cytomegalovirus infection and cytomegalovirus disease. The commercial launch of letermovir is estimated to be in August 2022.
Study: NCT06568887

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dextrose Water
Description: Individuals in this group will receive three injections of 5% dextrose water per week for six weeks period to treat their pain in sacroiliac joint and then their responce will b documented.
Study: NCT05383846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Narrative Exposure Therapy
Description: NET (Schauer et al., 2011) is an evidence-based, short-term, manualised treatment for complex trauma, aiming to reduce symptoms of traumatic stress in individuals. NET combines principles of CBT, Testimony Therapy, and Exposure Therapy.~This is a multiple baseline single case series design which focuses on assessing the posited exposure and autobiographical memory integration components of Narrative Exposure Therapy; no comparator will be included.
Study: NCT05850533

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Tai Chi Easy
Description: Unique to other mind-body therapies, Tai Chi Easy (TCE) is multi-component mind-body therapy including: 1) Gentle movement, 2) Breath practice, 3) Self-massage, and 4) Meditation.
Study: NCT06568887

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Injection
Description: Individuals in this group will receive three corticosteroid injections per week for a period of six weeks to treat their pain in Sacroiliac joint and then their responce will also be documented.
Study: NCT06359756

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning in carotid surgery
Description: After the initial declamping of the carotid artery the procedure is performed with 6 cycles of reperfusion of 30 seconds each (clamping of the internal carotid artery) which are successively followed by 6 cycles of ischemia lasting 30 seconds (clamping of the internal carotid artery). Clamping is done on the unaltered ICA, at the clamping site prior to performing CEA above the plaque termination point.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Eversion Carotid Endarterectomy
Description: Standard Eversion Carotid Endarterectomy
Study: NCT04504227

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Thin liquid swallows
Description: Thin liquid swallows of formula or breastmilk or other liquid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Slightly thickened liquid swallows
Description: Slightly thick liquid swallows of formula thickened with rice cereal or breastmilk or other liquid thickened with Gelmix

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mildly thickened liquid swallows
Description: Mildly thick liquid swallows of formula thickened with rice cereal or breastmilk or other liquid thickened with Gelmix

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moderately thickened liquid swallows
Description: Moderately thick liquid swallows of formula thickened with rice cereal or breastmilk or other liquid thickened with Gelmix
Study: NCT06159686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemp
Description: The application of the hemp-containing cream occurred in the morning and evening on the itching areas, excluding the face for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The application of the placebo cream occurred in the morning and evening on the itching areas, excluding the face for 4 weeks.
Study: NCT05415176

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Taurine supplementation
Description: Participants will receive 3g of taurine to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.
Study: NCT05288374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg
Description: Administering Celecoxib 100 mg (Celebrex) regularly every 12 hours for 3 days starting at 6 in the morning on the day of surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administering placebo regularly every 12 hours for 3 days starting at 6 in the morning on the day of surgery
Study: NCT05415176

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Taurine supplementation
Description: Participants will receive 3g of taurine to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pshysical exercise
Description: Participants will perform a multicomponent type workout that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 16 weeks
Study: NCT06536309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan
Description: Sacubitril-valsartan titrated to maximally targeted dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan titrated to maximally targeted dose
Study: NCT05010759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoTherm Ablation
Description: Iron nanoparticles are instilled into the prostate cancer lesion and then the particles are heated using a magnetic field and this heating ablates the prostate cancer lesion.
Study: NCT05929014

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral-Transcranial direct current stimulation (bilateral-tDCS)
Description: The tDCS is non-invasive brain stimulation technique applied over the participant's scalp using a reference to the International 10-20 electrode Placement System for EEG electrode placement. The cathodal and anodal electrodes will be applied over the right and left primary motor areas, respectively.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cathodal-Transcranial direct current stimulation (cathodal-tDCS)
Description: The tDCS is non-invasive brain stimulation technique applied over the participant's scalp using a reference to the International 10-20 electrode Placement System for EEG electrode placement. The cathodal electrode will be attached over the left primary motor area while the anodal will be applied over the right supraorbital.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham bilateral-tDCS
Description: Sham bilateral-tDCS
Study: NCT05415176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pshysical exercise
Description: Participants will perform a multicomponent type workout that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 16 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: The participants will receive a supplementation capsule containing placebo in the morning in single-dose capsules. The intervention will last 16 weeks.
Study: NCT05929014

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cathodal-tDCS
Description: Sham cathodal-tDCS
Study: NCT05219877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-urodynamic Levofloxacin
Description: Levofloxacin 500 mg single dosage 1 hour before the urodynamic examination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Post-urodynamic Levofloxacin
Description: Administering once daily Levofloxacin 500 mg for 3 days after urodynamic study
Study: NCT06243653

Intervention type: DIAGNOSTIC_TEST
Intervention: CMD test
Description: Measured CFR and IMR
Study: NCT06157931

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilient Student Training intervention (ReST)
Description: ReST consists of one individual 60-minute session and two 90-minute group-based sessions.
Study: NCT04925453

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: active tDCS and cognitive training intervention
Description: Intervention sessions will occur during Visits 2-6. Cognitive training will occur concurrently with tDCS in both the active and sham tDCS groups. Over each 46-minute daily training period, 4 of 5 BrainHQ training tasks will be performed for approximately 11 minutes in a randomly selected order. Order of task presentation will be randomized each session. Stimulation sequences will occur in the first 13 minutes (shut off: Minute 13) of the session and the last 13 minutes of the session (turn on: Minute 33). The Symptom Rating Questionnaire (SRQ) will be asked before and after stimulation to assess for any side-effects. The BrainHQ Task Load Index (TLX) will be administered at the end of each intervention session. At the end of Intervention Session 3, subjects will be given a Blinding Questionnaire which asks whether they thought they received active or sham treatment.
Study: NCT05858528

Intervention type: DIAGNOSTIC_TEST
Intervention: PEST screening questionnaire
Description: PEST questionnaire to screen for PsA performed every 6 months
Study: NCT05944900

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate glue application
Description: The wound must be positioned in a horizontal plane, and the glueapplied uniformly overhanging the wound. Cyanoacrylate glue is contraindicated when adhesion cannot be achieved.~Cyanoacrylate glue should be applied in accordance with the instructions for use.~Wound-closing properties are only fully achieved once the first layer has fully polymerized. This depends on skin type, skin hydration and ambient humidity. If a second layer is applied, the polymerization time is extended accordingly.
Study: NCT05944263

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weRISE; The gratitude, kindness and hope (GKH) program
Description: weRISE is an arts based train the trainer intervention that promotes positive mental health through cultivating gratitude, kindness and hope among youth in schools and informal settlements in India and Kenya

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The [adapted] Stan Kutcher Teen Mental Health (TMH) program
Description: The 'Teen Mental Health' curriculum developed by Dr. Stan Kutcher, aims to increase mental health literacy among young people ;will be used in the control group (active comparator group). The control intervention consists of eight sessions (45 minutes each) delivered by older groups of young people (ages 18-24) in schools and community settings through a didactic approach.
Study: NCT05776108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir IR Formulation (reference)
Description: Cabotegravir IR Formulation (reference) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir IR Formulation (reference)
Description: Cabotegravir IR Formulation (reference) will be administered.
Study: NCT04925453

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: sham tDCS and cognitive training intervention
Description: Intervention sessions will occur during Visits 2-6. Cognitive training will occur concurrently with tDCS in both the active and sham tDCS groups. Over each 46-minute daily training period, 4 of 5 BrainHQ training tasks will be performed for approximately 11 minutes in a randomly selected order. Order of task presentation will be randomized each session. Stimulation sequences will occur in the first and last 13 minutes of the session. For sham stimulation, the electrodes will be placed at the same positions as for active stimulation, but current will be ramped down immediately after the initial 30s ramp up period. The Symptom Rating Questionnaire (SRQ) will be asked before and after stimulation to assess for any side-effects. The BrainHQ Task Load Index (TLX) will be administered at the end of each intervention session. At the end of Intervention Session 3, subjects will be given a Blinding Questionnaire which asks whether they thought they received active or sham treatment.
Study: NCT06555133

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: yttrium-90 radioembolization
Description: yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals who have been treated with two or more lines of systemic therapy.
Study: NCT06576375

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: oral Dapagliflozin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: oral metformin
Study: NCT05851612

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: constant PEEP
Description: Constant PEEP of 5 cm H2O will be applied and maintained throughout one-lung ventilation.
Study: NCT05776108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir IR Formulation (reference)
Description: Cabotegravir IR Formulation (reference) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir IR Formulation (reference)
Description: Cabotegravir IR Formulation (reference) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir DT Formulation (test 1)
Description: Cabotegravir DT Formulation (test 1) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir DT Formulation (test 1)
Description: Cabotegravir DT Formulation (test 1) will be administered.
Study: NCT05851612

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Driving pressure guided PEEP
Description: PEEP titration will be started at 5 cmH2O and then increased in 1 cmH2O interval to 10 cmH2O. After 10 breath cycles will maintained, Driving pressure (ΔP) will be measured at each PEEP level at the last cycle. The PEEP indicating the lowest ΔP will be selected if multiple levels of PEEP showed the same lowest ΔP, the lowest PEEP will be selected. Driving pressure will be calculated as plateau pressure minus PEEP. Titration will stopped if peak inspiratory pressure of 50 cm H2O, or plateau pressure of 40 cm H2O reached, or hypotension will be observed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: oxygenation method guided PEEP
Description: PEEP titration will be started from 5 cmH2O and increase of 1 cmH2O every 4 min with fixed driving pressure that will result in delivery of a fixed tidal volume (TV) of 6ml/kg ideal body weight (IBW). Optimal PEEP will be defined as the PEEP below which PaO2 /FIO2 falls by at least 20%. If at least 20% PaO2 /FIO2 decrement is not obtained, then PEEP that will result in the highest PaO2 will be selected.
Study: NCT05776108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir DT Formulation (test 1)
Description: Cabotegravir DT Formulation (test 1) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir DT Formulation (test 1)
Description: Cabotegravir DT Formulation (test 1) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir DT Formulation (test 1)
Description: Cabotegravir DT Formulation (test 1) will be administered.
Study: NCT06474234

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Bifidobacterium infantis YLGB-1496 at 1x10 log CFU/day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention consists of daily administration of 2g of maltodextrin, administered daily for 12-weeks)
Study: NCT05776108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir DT Formulation (test 1)
Description: Cabotegravir DT Formulation (test 1) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir DT Formulation (test 2)
Description: Cabotegravir DT Formulation (test 2) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir DT Formulation (test 2)
Description: Cabotegravir DT Formulation (test 2) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir DT Formulation (test 2)
Description: Cabotegravir DT Formulation (test 2) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir DT Formulation (test 2)
Description: Cabotegravir DT Formulation (test 2) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir DT Formulation (test 2)
Description: Cabotegravir DT Formulation (test 2) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir DT Formulation (test 2)
Description: Cabotegravir DT Formulation (test 2) will be administered.
Study: NCT04800913

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Multimodal imaging
Description: Preoperative 2D/3D TOE and MDCT, operative 2D/3D TOE and fluoroscopy/angiography, postoperative 2D/3D TOE and MDCT

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standard imaging
Description: Preoperative MDCT, operative 2D/3D TOE and fluoroscopy/angiography, postoperative 2D/3D TOE and MDCT
Study: NCT04798300

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Newly Introduced Gradient Monolithic Zirconia
Description: Fabrication of full-coverage crowns over posterior teeth using Newly Introduced Gradient Monolithic Zirconia to measure wear

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full Strength Monolithic Zirconia
Description: Fabrication of full-coverage crowns over posterior teeth using Full Strength Monolithic Zirconia to measure wear